Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

The deal includes over $200 million in upfront and near-term payments to Septerna. The move is part of Novo Nordisk’s broader strategy to expand its presence in the highly competitive obesity ...

Pharmaceutical giant Novo Nordisk inks a $2.2 billion deal with biotech company Septerna to develop a GLP-1 weight-loss drug in the form of an oral pill.Septerna's stock is skyrocketing by over 60 ...

COPENHAGEN, May 14 (Reuters) - Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more here.

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Novo Nordisk said Wednesday that it will work ... a more convenient weight loss treatment to the market. Under the deal, Septerna, which specializes in making small-molecule drugs, is eligible ...

The deal includes over $200 million in upfront and near-term payments to Septerna. The move is part of Novo Nordisk’s broader strategy to expand its presence in the highly competitive obesity ...